Comparison of prognosis between oncocytic thyroid carcinoma and follicular thyroid carcinoma: a population-based propensity score matching analysis
- PMID: 39259318
- DOI: 10.1007/s00405-024-08965-7
Comparison of prognosis between oncocytic thyroid carcinoma and follicular thyroid carcinoma: a population-based propensity score matching analysis
Abstract
Background: Oncocytic thyroid carcinoma (OTC) is a rare subtype of thyroid cancer known for its distinctive morphology and high likelihood of recurrence, setting it apart from follicular thyroid carcinoma (FTC). Despite this, there is limited research comparing the clinicopathological characteristics and outcomes of OTC and FTC.
Methods: We retrospectively searched through the Surveillance, Epidemiology, and End-Results (SEER) database (2004-2015) for histologically diagnosed OTC and FTC patients. Kaplan-Meier analysis, propensity score matching (PSM), univariate Cox proportional risk regression model, and subgroup analysis were employed to investigate the prognostic effect of clinicopathological features and treatment regimens on survival outcomes of OTC and FTC patients.
Results: 2329 OTC patients and 5679 FTC patients were included in the study. OTC patients were prone to older age, white race, lymph node metastasis, distal metastasis, extension and multiple primary tumors compared with FTC patients. After using a 1:1 PSM matching ratio, there were no significant differences in demographic and clinicopathological characteristics between the matched groups. Further Cox regression analysis showed that OTC patients had lower overall survival (OS) and cancer-specific survival (CSS) in contrast with FTC patients. Subgroup survival analysis suggested that the OTC patients were related to lower OS in subgroups including those over 55 years old, male sex, white ethnicity, extrathyroidal extension, single primary tumor, surgery and without chemotherapy compared with the FTC patients in these subgroups. In addition, the OTC patients were connected with lower CSS in subgroups including male sex, white ethnicity, married status, tumor size is less than 20 mm or more than 40 mm, N0 stage, localized stage, single primary tumor, surgery, radiotherapy, and without chemotherapy compared with the FTC patients in these subgroups. Meanwhile, the OTC patients had lower CSS compared to FTC patients regardless of age and extrathyroidal extension.
Conclusions: The results suggested that OTC patients have unique clinical features and poorer prognoses compared to FTC patients. Surgical resection and radioactive iodine therapy are recommended for OTC patients and FTC patients. It is worth noting that the prognosis of OTC relies largely on the selection of treatment strategies. Therefore, our results highlighted the clinical significance of the early distinguishment and the correct choice of treatment in OTC patients.
Keywords: Follicular thyroid carcinoma; Oncocytic thyroid carcinoma; Prognosis; SEER.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare they have no competing interests. Ethical approval: The data analyzed in the present study was collected from the SEER database, which contained the de-identified information for patients; therefore, this article was exempted from approval by the Institutional Review Board.
Similar articles
-
Rare but Complex: Outcomes and Challenges in Managing Composite Follicular-Anaplastic Thyroid Cancer.Ann Surg Oncol. 2025 Jul;32(7):4754-4759. doi: 10.1245/s10434-025-17208-w. Epub 2025 Mar 25. Ann Surg Oncol. 2025. PMID: 40131622
-
Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.J Clin Endocrinol Metab. 2025 Apr 22;110(5):e1343-e1350. doi: 10.1210/clinem/dgae581. J Clin Endocrinol Metab. 2025. PMID: 39166490 Free PMC article.
-
Clinical and Histopathological Risk Factors for Radioactive Iodine-Refractory Follicular and Oncocytic Thyroid Carcinoma.J Clin Endocrinol Metab. 2024 Nov 18;109(12):e2334-e2341. doi: 10.1210/clinem/dgae084. J Clin Endocrinol Metab. 2024. PMID: 38349206 Free PMC article.
-
Follicular thyroid cancer.Endocrinol Metab Clin North Am. 1995 Dec;24(4):761-801. Endocrinol Metab Clin North Am. 1995. PMID: 8608779 Review.
-
Management of follicular thyroid carcinoma.Eur Thyroid J. 2024 Oct 16;13(5):e240146. doi: 10.1530/ETJ-24-0146. Print 2024 Oct 1. Eur Thyroid J. 2024. PMID: 39419099 Free PMC article. Review.
Cited by
-
The Revolution of Targeted Therapies in Thyroid Cancer Treatment: Present and Future Promising Anti-Cancer Drugs.Int J Mol Sci. 2025 Apr 12;26(8):3663. doi: 10.3390/ijms26083663. Int J Mol Sci. 2025. PMID: 40332222 Free PMC article. Review.
References
-
- Wu MH, Lee YY, Lu YL et al (2022) Risk factors and prognosis for metastatic follicular thyroid cancer. Front Endocrinol 13:791826 - DOI
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous